Geneva, April 28 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122736) titled 'A multicenter, randomized, open-label, positive-controlled Phase III clinical study on the efficacy and safety of recombinant human growth hormone injection (GB06) in treating growth disorders caused by growth hormone deficiency in children' on April 16.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China
Condition:
Growth disorder caused by insufficient growth hormone secretion in children
Intervention:
Test group:Study drug GB06
Recruitment Status: Not Recru...